Unión Europea - griego - EMA (European Medicines Agency)

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - Οφθαλμολογικά - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Unión Europea - griego - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Οφθαλμολογικά - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Unión Europea - griego - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - Οφθαλμολογικά - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Unión Europea - griego - EMA (European Medicines Agency)

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - Οφθαλμολογικά - Το lucentis ενδείκνυται σε ενήλικες για:Τη θεραπεία της νεοαγγειακής (υγρής μορφής) ηλικιακής εκφύλισης της ωχράς κηλίδας (amd), Η θεραπεία της όρασης που οφείλεται σε χοριοειδική νεοαγγείωση (cnv)από Την επεξεργασία της όρασης λόγω διαβητικού οιδήματος της ωχράς κηλίδας (dme), Η θεραπεία της όρασης λόγω οιδήματος της ωχράς κηλίδας δευτερεύουσα σε απόφραξη φλέβας του αμφιβληστροειδούς (υποκατάστημα rvo ή κεντρική rvo).

Unión Europea - griego - EMA (European Medicines Agency)

roche registration gmbh - polatuzumab vedotin - Το Λέμφωμα Β-Κυττάρων - Αντινεοπλασματικοί παράγοντες - polivy σε συνδυασμό με bendamustine και rituximab ενδείκνυται για τη θεραπεία ενήλικων ασθενών με υποτροπιάζον/ανθεκτικό διάχυτο από μεγάλα Β-κύτταρα λέμφωμα (dlbcl) που δεν είναι υποψήφιοι για αιματοποιητική μεταμόσχευση βλαστικών κυττάρων. polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (r-chp) is indicated for the treatment of adult patients with previously untreated diffuse large b-cell lymphoma (dlbcl).

Unión Europea - griego - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - risankizumab - psoriasis; arthritis, psoriatic - Ανοσοκατασταλτικά - plaque psoriasisskyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. psoriatic arthritisskyrizi, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (dmards). crohn's diseaseskyrizi is indicated for the treatment of adult patients with moderately to severely active crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.

Grecia - griego - Εθνικός Οργανισμός Φαρμάκων

novartis (hellas) a.e.b.e. 12ο χλμ. Εθν.οδού Νο1,, 144 51 144 51, Μεταμόρφωση Αττικής 2811712 - ranibizumab - inj.sol (ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ) - 10mg/ml - ranibizumab 0 = 10mg

Grecia - griego - Εθνικός Οργανισμός Φαρμάκων

merck & co inc., n.j., usa one merck drive, whitehouse station, - pembrolizumab - ly.p.iv.in (ΕΝΕΣΙΜΟ ΛΥΟΦΙΛΟ ΓΙΑ ΕΝΔΟΦΛΕΒΙΑ ΕΓΧΥΣΗ) - 50mg/vial - pembrolizumab 50mg - not yet assigned

Grecia - griego - Εθνικός Οργανισμός Φαρμάκων

immunomedics inc., usa , - sacituzumab govitecan - pd.i.s.inf (ΚΟΝΙΣ ΓΙΑ ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ/ΔΙΑΛΥΜΑ ΠΡΟΣ ΕΓΧΥΣΗ) - 180 mg/vial - sacituzumab govitecan 180mg - antineoplastic agents

Grecia - griego - Εθνικός Οργανισμός Φαρμάκων

ΙΦΕΤ ΑΕ - ranibizumab - ΕΝΕΣΙΜΟ ΔΙΑΛΥΜΑ - 10mg/ml - 0347396821 - ranibizumab - 0.000000